Fig. 4

E2F7 stabilizes resistance in GBM cell lines in a p53-dependent manner. (A) Schematic representation of the candidate transcription factor screening approach, using ChIPBase and PROMO databases. (B) Correlation between E2F7 and TP53 in TCGA_GBM database (Spearman’s rank correlation test). (C) The p53 and phosphorylation p53 (Ser46) expression in TMZ-S and TMZ-R tissue and tissue derived cells, GAPDH served as a loading control. The quantification of p-p53 and p53. (D) Relative luciferase activity of p53 in TMZ-S and TMZ-R cells (n = 3, *p < 0.05). (E) Western blot analysis of E2F7 and p53 expression in the indicated TMZ-S cells. (F) Western blot analysis of E2F7 and p53 expression in the indicated TMZ-S cells treated with Dox. (G) Predicted P53-binding sites in the promoter region of E2F7 using JASPAR database. TSS: transcriptional start site. (H) The relative enrichment compared to that of input of TMZ-S and TMZ-R cells at the potential p53 binding sites (n = 3, **p < 0.01)